The stock price performance for the year has been a mixed bag, indicating either a pessimistic or optimistic outlook depending on how you look at it. Year to date metric has recorded a loss of -84.86%.However, over the last six months, we can see a stronger performance of -56.80%. Over the last 30 days, the price of BNGO has fallen by 20.11%. And in the last five days, it has surged by 46.72%.
Bionano Genomics Inc experienced a rather shaky stock market performance. The highest value in the past year was recorded at $2.27 on 01/02/24 and the lowest value was $0.19 on 12/24/24.
52-week price history of BNGO Stock
Analyzing a stock’s 52-week high and low prices can offer important information about its present condition and future outlook. Bionano Genomics Inc’s current trading price is -87.40% away from its 52-week high, while its distance from the 52-week low is 47.47%. The stock’s price range during this period has varied between$0.19 and $2.27. The Bionano Genomics Inc’s shares, which operate in the Healthcare, saw a trading volume of around 40.71 million for the day, a figure considerably higher than their average daily volume of 2.96 million over last three months.
Market Capitalization vs. Financial Performance: A Comparative Study
Bionano Genomics Inc (BNGO) has experienced a quarterly decline of -36.97% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 28.37M and boasts a workforce of 344 employees.
Combining Moving Average and Trading Volume Data for Better Market Insight
Based on Barchart.com data, the company’s moving average over the 100-day period was 0.3489, with a change in price of -0.1455. Similarly, Bionano Genomics Inc recorded 2,884,432 in trading volume during the last 100 days, posting a change of -33.71%.
BNGO’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look
The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for BNGO stands at 0.46. Similarly, the long-term debt-to-equity ratio is also 0.11.
BNGO Stock Stochastic Average
Bionano Genomics Inc’s raw stochastic average for the past 50 days is presently 50.60%, as of today. This marks a decrease from the raw stochastic average of the last 20 days, which was 59.50%. Additionally, the company’s Stochastic %K and %D values for the past 20 days were 34.41% and 22.36%, respectively.
